On January 12, 2021 GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, reported preliminary, unaudited net product sales for the fourth quarter and full year 2020 and key priorities for 2021 (Press release, GW Pharmaceuticals, JAN 12, 2021, View Source [SID1234573906]). Justin Gover, GW’s Chief Executive Officer, expects to discuss these updates as part of a webcast presentation at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 12th at 10:00 a.m. ET.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Epidiolex sales increased by over 70% in 2020 despite the challenges of COVID-19, reflecting the positive impact this medicine has on patients as well as the performance of our commercial team. We remain encouraged by our patients’ experience on this product, as demonstrated by high persistence and refill rates. This, combined with our expansion of payer coverage and the recently approved Tuberous Sclerosis Complex indication, leads us to expect continued strong growth in 2021 in both the US and Europe," said Justin Gover, GW’s Chief Executive Officer. "Our goals in 2021 include driving further Epidiolex growth and advancing multiple US pivotal trials for nabiximols in the treatment of MS spasticity, with the first data readout expected this year. In addition to our previously announced pipeline activities, we are leveraging our world leadership in cannabinoid science to design and synthesize novel cannabinoid molecules and expect our first novel product candidate to enter the clinic in 2021."
Preliminary Unaudited Fourth Quarter and Full-Year 2020 Net Product Sales
Based on preliminary unaudited financial information, the Company expects total net product sales to be approximately $148 million for the fourth quarter and approximately $526 million for the year ended December 31, 2020. Total net product sales of Epidiolex are expected to be approximately $144 million for the fourth quarter, comprising $129 million in the US and $15 million ex-US. Total net product sales of Epidiolex for the year ended December 31, 2020 are expected to be approximately $510 million compared to $296 million in 2019. Cash and cash equivalents at December 31, 2020 were approximately $486 million.
Key Priorities for 2021
EPIDIOLEX commercialization:
Continue to drive revenue growth in US and Europe:
• Execute on TSC label expansion and continued penetration in Dravet and LGS
• Build further on expanded payer coverage achievements
• Accelerate adoption across a broader prescriber base
• Increase penetration in long-term care segment
• Continue launches in Germany and UK and achieve successful pricing and reimbursement, and launch execution in France, Spain and Italy, as well as other European countries
• Obtain approval of the Tuberous Sclerosis Complex indication in Europe
Supplement existing 14 Orange Book listed patents (expiry 2035) with additional use patents, and obtain grant of the Epidiolex "composition" patent
Commence pivotal trial in fourth target orphan epilepsy indication
Nabiximols in the US:
Continue recruitment of two ongoing pivotal MS spasticity trials and commence three additional pivotal trials in MS spasticity
Achieve data from at least one pivotal MS spasticity trial in 2021
NDA submission expected following first positive pivotal MS spasticity trial
Commence clinical program to expand future label to include spasticity associated with Spinal Cord Injury
Additional pipeline:
Continue recruitment of ongoing Phase 2b study of a cannabidiol formulation for the treatment of schizophrenia
Conduct placebo-controlled trials with both CBDV and CBD in autism
Advance NHIE clinical program utilizing an intravenous formulation of cannabidiol
Complete Phase 1 trial for novel botanical drug candidate GW541
Advance first novel NCE cannabinoid candidate into Phase 1